126 related articles for article (PubMed ID: 12409423)
1. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001).
Jones RN; Mutnick AH; Varnam DJ
J Clin Microbiol; 2002 Nov; 40(11):4332-3. PubMed ID: 12409423
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations.
Sahm DF; Thornsberry C; Mayfield DC; Jones ME; Karlowsky JA
J Clin Microbiol; 2002 Feb; 40(2):669-74. PubMed ID: 11825993
[TBL] [Abstract][Full Text] [Related]
3. Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003.
Master RN; Draghi DC; Jones ME; Thornsberry C; Sahm DF; Karlowsky JA
Ann Clin Microbiol Antimicrob; 2004 Jan; 3():1. PubMed ID: 14713319
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Jones RN; Jenkins SG; Hoban DJ; Pfaller MA; Ramphal R
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):93-8. PubMed ID: 10863103
[TBL] [Abstract][Full Text] [Related]
5. Impact of the revised penicillin susceptibility breakpoints for Streptococcus pneumoniae on antimicrobial resistance rates of meningeal and non-meningeal pneumococcal strains.
Al-Waili BR; Al-Thawadi S; Hajjar SA
Ann Saudi Med; 2013; 33(2):111-5. PubMed ID: 23562996
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Yee YC; Thornsberry C; Brown SD; Bouchillon SK; Marler JK; Rich T
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():13-9. PubMed ID: 8150756
[TBL] [Abstract][Full Text] [Related]
7. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).
Jones RN; Sader HS; Mendes RE; Flamm RK
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):107-9. PubMed ID: 23009730
[TBL] [Abstract][Full Text] [Related]
8. Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae.
Karlowsky JA; Jones ME
J Antimicrob Chemother; 2003 Feb; 51(2):467-8. PubMed ID: 12562727
[No Abstract] [Full Text] [Related]
9. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18.
Su LH; Wu TL; Kuo AJ; Chia JH; Chiu CH
J Antimicrob Chemother; 2009 Aug; 64(2):336-42. PubMed ID: 19520718
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.
Tan TQ; Schutze GE; Mason EO; Kaplan SL
Antimicrob Agents Chemother; 1994 May; 38(5):918-23. PubMed ID: 8067771
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
Fenoll A; Aguilar L; Robledo O; Giménez MJ; Granizo JJ; Biek D; Tarragó D
Antimicrob Agents Chemother; 2008 Nov; 52(11):4209-10. PubMed ID: 18725443
[No Abstract] [Full Text] [Related]
12. Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003).
Pottumarthy S; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Feb; 51(2):147-50. PubMed ID: 15698723
[TBL] [Abstract][Full Text] [Related]
13. Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections.
Jacobs RF; Kaplan SL; Schutze GE; Dajani AS; Leggiadro RJ; Rim CS; Puri SK
Antimicrob Agents Chemother; 1996 Apr; 40(4):895-8. PubMed ID: 8849247
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
15. Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
Kim BN; Woo JH; Kim YS; Ryu J; Kim MN; Pai CH
Chemotherapy; 2000; 46(5):303-8. PubMed ID: 10965094
[TBL] [Abstract][Full Text] [Related]
16. Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae--United States, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Feb; 53(7):152-4. PubMed ID: 14985653
[TBL] [Abstract][Full Text] [Related]
17. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.
Stratton CW; Aldridge KE; Gelfand MS
Diagn Microbiol Infect Dis; 1995; 22(1-2):35-42. PubMed ID: 7587048
[TBL] [Abstract][Full Text] [Related]
18. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis.
Olivier C; Cohen R; Begué P; Floret D
Pediatr Infect Dis J; 2000 Oct; 19(10):1015-7. PubMed ID: 11055609
[No Abstract] [Full Text] [Related]
19. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
Jorgensen JH; Swenson JM; Tenover FC; Barry A; Ferraro MJ; Murray PR; Reller LB
J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
[TBL] [Abstract][Full Text] [Related]
20. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.
Weinstein MP; Klugman KP; Jones RN
Clin Infect Dis; 2009 Jun; 48(11):1596-600. PubMed ID: 19400744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
